Article

First Diabetic Glucometer for the iPhone Now Available in Europe

Sanofi-Aventis and AgaMatrix are unveiling a device that combines an advanced glucometer with an iOS app that lets patients share data with providers.

This article originally appeared at iMedicalApps.com, part of the HCPLive network.

Seemingly ages ago, in a 2009 Steve Jobs presentation unveiling the new features of iPhone OS 3.0 (before it was renamed iOS), a J&J company named Lifescan demonstrated a device that took advantage of Apple’s newly provided connectivity to the 30 pin dock connector.

The demonstration produced ripples of interest in the medical community since it was the first glimpse of how hardware and software could work together to extend smartphones into real medical devices that follow patients wherever they go. However, in an interview with Mobihealthnews, the company admitted that it was just a demonstration unit without a clear path to commercialization at that time.

Now, Sanofi-Aventis and AgaMatrix have unveiled a commercial device that combines an advanced glucometer with an iOS app that shares glucose data with patients’ providers. As Medgadget reported, the product still requires 510(k) approval before being deployed as a medical device. At this time, it is not clear when this might occur.

To read the entire article, click here.

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.